OncoHost announced a collaboration with Gustave Roussy to identify non-invasive biomarkers for immune-related adverse events (irAEs) in patients undergoing immunotherapy.
The PREMIS study, promoted by Gustave Roussy, is an interventional research aimed at identifying predictive biomarkers for irAEs in patients receiving immunotherapy. As part of this broader effort, OncoHost is partnering with Gustave Roussy to further validate its PROphetirAE test—an advanced tool that utilizes AI and biomarker analysis to assess patients' risk of developing irAEs. This collaboration supports the study’s goal of enabling personalized treatment strategies that minimize toxicities and improve therapeutic outcomes.
The initiative designed specifically to identify biomarkers that can predict the onset of immune-related adverse events (irAEs), has enrolled 1,000 cancer patients receiving immunotherapy with monoclonal antibodies (anti-PD-1, anti-PD-L1, anti-CTLA4, and combinations). This unique study is built within a dedicated pharmacovigilance department, allowing for the systematic collection of key clinical data and comprehensive characterization of irAEs.
Results from the translational analysis of the PREMIS study will not only authenticate OncoHost’s PROphetirAE test but also provide new insights into the biological mechanisms behind irAEs. The data will contribute to the development of prevention strategies and personalized approaches to managing immunotherapy-related toxicities, paving the way for safer and more effective treatments.
